Incident Hyperuricemia in Relation to Antihypertensive Therapy with the Irbesartan/hydrochlorothiazide Combination.

Di Zhang,Qi-Fang Huang,Yan Li,Ji-Guang Wang

DOI: https://doi.org/10.1097/mbp.0000000000000554

2021-01-01

Blood Pressure Monitoring

Abstract:Objective We investigated serum uric acid changes and incident hyperuricemia in relation to the achieved blood pressure (BP) after 12 weeks of antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. Methods The study participants were 449 patients who completed the study. Analysis of covariance and multiple logistic regression analyses were performed to calculate the least square mean changes (+/- standard error) from baseline in serum uric acid and odds ratios (ORs) for incident hyperuricemia according to the achieved levels of BP. Results Adjusted analyses showed that serum uric acid changes differed according to the achieved SBP/DBP (P = 0.002), with a smaller mean (+/- standard error) increase in the range of 130-139/<90 mm Hg (n = 132, 19.8 +/- 5.7 mu mol/L) than that of >= 140/90 (n = 129, 32.4 +/- 7.3 mu mol/L) or <130/90 mm Hg (n = 188, 39.5 +/- 5.1 mu mol/L). Adjusted analyses showed similar results for the incident hyperuricemia (n = 95, 24.0%) in those patients with normal serum uric acid at baseline (n = 396). The risk of incident hyperuricemia was lower (OR, 0.45; 95% confidence interval 0.25-0.83; P = 0.04) in patients with an achieved SBP/DBP of 130-139/<90 mm Hg (n = 117, incidence rate, 17.1%) than those with an achieved SBP/DBP of >= 140/90 (n = 118, 31.4%) or <130/90 mm Hg (n = 161, 23.6%). Conclusions Thiazide-induced changes in serum uric acid or incident hyperuricemia were associated with the achieved SBP/DBP, being lower at the level of 130-139/<90 mm Hg.